HC Wainwright Reaffirms Buy Rating for Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $27.00 price target on the stock. HC Wainwright's target price points to a potential upside of 158.62% from the stock's previous close. HC Wainwright also issued estimates for Celcuity's Q2 2025 earnings at ($0.99) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.92) EPS, Q1 2026 earnings at ($1.09) EPS, Q2 2026 earnings at ($1.13) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($4.11) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at $1.26 EPS and FY2029 earnings at $3.26 EPS.

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a research note on Thursday, May 15th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Celcuity currently has a consensus rating of "Buy" and a consensus price target of $30.80.

Celcuity Stock Down 2.9%

Shares of NASDAQ:CELC traded down $0.31 on Monday, reaching $10.44. The company had a trading volume of 144,757 shares, compared to its average volume of 298,558. Celcuity has a twelve month low of $7.58 and a twelve month high of $19.77. The stock has a 50-day moving average price of $10.19 and a 200 day moving average price of $11.53. The stock has a market capitalization of $395.32 million, a P/E ratio of -4.00 and a beta of 0.56. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. On average, equities analysts expect that Celcuity will post -2.62 EPS for the current year.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. increased its stake in Celcuity by 49.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after acquiring an additional 1,132 shares during the period. Aquatic Capital Management LLC acquired a new stake in Celcuity during the fourth quarter valued at approximately $50,000. Focus Financial Network Inc. acquired a new stake in Celcuity during the first quarter valued at approximately $108,000. Perkins Capital Management Inc. acquired a new stake in Celcuity during the first quarter valued at approximately $115,000. Finally, GAMMA Investing LLC boosted its holdings in Celcuity by 1,237.4% during the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after purchasing an additional 1,225 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.